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dimensions of health within three levels of severity, 
and the self-rated heath status recorded on EQ-visual 
analogue scale (VAS). The overall HRQOL can be 
used to derive utility values between 0 (dead) and 
1 (full health). The overall finding shows lower 
mean utility scores and VAS scores in patients 
with progressive disease compared with those with 
progression-free disease (0.58 vs. 0.70 and 53.7 
vs. 66.6, respectively). The EQ-VAS also showed a 
decreased score with later lines of treatment. This 
study indicates a substantial impact of lung cancer 
on HRQOL of patients, with stage IV disease, later 
line of treatment and progressive disease resulting 
in utility deterioration. The data from this study 
will help inform cost-utility assessment for NSCLC 
therapies. (p. 997)
Photo credit: Mike Blackburn (http://www.flickr.com/
photos/mikeblackburn/5520196331/)
•	 Detection of ALK Positive 
Non-Small Cell Lung 
Cancers on Cytological 
Specimens: High Accuracy 
of Immunocytochemistry 
with the 5A4 Clone
monoclonal antibody from which staining intensity and 
% of stained cancer cells were obtained blindly to the 
FISH profiles. Any ICC staining denotes a positive result. 
Review of slide for ICC and FISH signals was conducted 
if discrepancy occurred. The findings revealed ALK 
ICC-positivity in the majority of cancer cells in 37.5% of 
the specimens. Compared to the FISH profiles, the ALK 
ICC staining only demonstrated one false negative and 
one false positive. With high sensitivity (93%), specificity 
(96%), positive (93%) and negative (96%) predictive 
values, the ALK ICC was considered a highly accurate 
method to detect ALK reaarangements in NSCLC.  
(p. 1004)
IN THIS ISSUE
Health-related quality of life (HRQOL) is significantly affected 
by NSCLC. The authors conducted an international prospective 
cross-sectional patient survey to measure health state utility 
values in advanced NSCLC patients and to determine factors 
that predict health state utility values. HRQOL was evaluated 
using the EuroQol (EQ-5D) questionnaire on patients from 
25 hospitals across Europe, Canada, Australia, and Turkey. 
The EQ-5D is a generic HRQOL measure that includes five 
The use of immunocytochemistry (ICC) for accurately detecting ALK 
rearrangement has been evaluated in cytological specimens of non-
small cell lung cancer (NSCLC) because the current gold standard 
for detection, fluorescence in situ hybridization (FISH), is expensive 
and complex to interpret. This retrospective analysis included 41 
NSCLC specimens with ALK FISH profiles, of which 14/41 (34.1%) 
were FISH-positive. The specimens were stained with the 5A4 
•	 A Pooled Analysis of 
Limited Stage Small Cell 
Lung Cancer Patients 
Treated with Induction 
Chemotherapy Followed 
by Concurrent Platinum-
Based Chemotherapy and 
70 Gy Daily Radiotherapy: 
CALGB 30904
Concurrent platinum-based chemotherapy and 
radiotherapy regimen of 45 Gray (Gy) in 1.5 Gy 
twice-daily fractions followed by prophylactic cranial 
radiotherapy are the current standard of care for 
patients with limited stage small cell lung cancer 
(L-SCLC). Salama et al. reported the outcomes of 
a pooled analysis of three consecutive prospective 
Cancer and Leukemia Group B (CALGB) trials to 
determine if high-dose once-daily radiotherapy could 
be an alternative to the current twice-daily radiotherapy 
for L-SCLC, which has not been widely accepted. 
This analysis formed the largest prospective database 
of patients treated with high-dosage once-daily 
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•	 Tumor Heterogeneity 
Measured on the CT 
Component of PET/
CT Predicts Survival in 
Patients with Potentially 
Curable Non-Small Cell 
Lung Cancer
In this prospective study, the prognostic potential of positron emission 
tomography/computed tomography (PET/CT) derived tumor textural 
heterogeneity in patients with non-small cell lung cancer (NSCLC) was 
assessed and compared to tumor staging and other imaging parameters 
(metabolism and vascularity). The feasibility study was conducted in 
56 NSCLC patients undergone combined fluorodeoxyglucose (FDG)-
PET/CT while the validation study in 66 NSCLC patients undergone 
combined FDG-PET/CT-dynamic contrast enhanced (DCE)-CT. These 
radiotherapy and concurrent platinum-based chemotherapy for 
L-SCLC. Two hundred patients were assessed for toxicity, disease 
control and survival, and were followed up for a median of 78 
months. The findings demonstrated a 23% of grade 3 or greater 
toxicity, a median overall survival (OS) of 19.9 months, a 5-year 
OS rate of 20% and a 2-year progression free survival rate of 26%. 
The authors concluded that a radiotherapy regimen of 70 Gy in 2 
Gy once-daily was well-tolerated with similar survival to the twice-
daily regimen. An ongoing intergroup study (CALGB 30610) is 
underway to determine whether 70 Gy once-daily radiotherapy 
is better than the standard care. The outcome of this analysis 
could guide decision of practitioners in providing high-dose daily 
radiotherapy concurrently with platinum-based chemotherapy for 
L-SCLC patients outside of clinical trial. (p. 1043)
•	 Tumor Volume Decrease at 
8 weeks is Associated with 
Longer Survival in EGFR-
mutant Advanced Non-
Small-Cell Lung Cancer 
Patients treated with EGFR 
Tyrosine Kinase Inhibitor
Tumor volumes of dominant lung lesions were measured on 
baseline and follow-up CT scans. Comparing with baseline scan, 
the median tumor volume was 59% smaller in follow-up scans 
at 8 weeks. This change was associated with survival: With a 
tumor volume decrease of more than 75%, patients had a median 
overall survival of 43.5 months and a median progression-free 
survival of 12.6 months compared to 16.3 months and 5.5 months, 
respectively, in patients with a tumor volume decrease of less than 
75%. This study demonstrated that tumor volume decrease at 8 
weeks is predictive of survival in patients with advanced NSCLC 
harboring EGFR activating mutations receiving treatment with 
first-line EGFR TKIs. This finding warrants further study in larger 
cohorts. (p. 1059)
Nishino et al. evaluated the association between tumor volume 
changes at 8 weeks of therapy and the outcomes in 56 advanced 
non-small cell lung cancer (NSCLC) patients bearing EGFR 
activating mutations and receiving EGFR tyrosine kinase inhibitor 
(TKI) treatment, first-line erlotinib or gefitinib in this study. 
RESEARCH WATCH
•	 Tivantinib (ARQ 197) 
Antitumor Activity is More 
Than Just c-MET Inhibition
crizotinib underwent G
0
–G
1
 cell cycle arrest while tivantinib 
treatment induced G
2
-M arrest, which resembles the effect of 
vincristine (microtubule targeting compound) treatment. Using 
COMPARE analysis by in silico screening of 39 cancer cell lines 
(JFCR39) for drug sensitivities, they showed that tivantinib also 
targets microtubule, apart from c-MET. Further in vitro study 
demonstrated that tivantinib inhibits microtubule polymerization, 
supporting the result from COMPARE analysis and revealed another 
mechanism of action of tivantinib, in addition to c-MET inhibition, 
in suppressing cancer cell viability. Taken together, the findings 
suggest that the anti-microtubule activity of tivantinib could make 
it an effective compound in other solid cancers. This result may 
also mean that its combination with erlotinib in NSCLC may not be 
the most active because they were developed based on the fact that 
tivantinib is a c-MET inhibitor. Further studies are needed to dissect 
the mechanism of tivantinib inhibiting microtubule function so most 
effective treatment could be achieved.
Katayama R, Aoyama A, Yamori T, et al. Cytotoxic activity of 
tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer 
Res 2013;73:3087–3096.
Tivantinib (ARQ 197) was initially reported as a selective c-MET 
inhibitor, which showed antitumor activity in early clinical 
trials with erlotinib in KRAS mutant non-small-cell lung cancer 
(NSCLC). The authors aimed to determine if c-MET inhibition is 
the sole mechanism of antitumor activity exhibited by tivantinib. In 
order to demonstrate if c-MET inhibition is involved, the activity of 
tivantinib and other c-MET inhibitors (crizotinib and PHA-665752) 
were compared in both c-MET-addicted and nonaddicted cancer 
cells. The study showed that both crizotinib and PHA-665752 
expectedly inhibited cell growth only in c-MET-addicted cancers. 
In contrary, tivantinib exhibited antitumor activity in both c-MET-
addicted and nonaddicted cells, with similar potency. This finding 
suggests that the antitumor activity of tivantinib is independent 
of c-MET. Furthermore, the cells treated with PHA-665752 or 
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•	 Disrupting Oncogenic 
KRAS Signaling by Small 
Molecule Inhibitor of the 
KRAS–PDEδ Interaction
the growth of RAS-mutant cancer cells. Subsequently, the authors 
of the present study identified a small-molecule inhibitor of PDEδ, 
called deltarasin, via high-throughput screening and structure-based 
hit optimization. Deltarasin selectively and potently binds to the 
prenyl-binding site of PDEδ, interfering with RAS signaling and 
inhibiting in vitro and in vivo growth of pancreatic cancer cells 
bearing mutant KRAS. The findings of this study illustrate a strategy 
that rekindles the dampened interests in targeting RAS oncogenic 
signaling and would drive more efforts in novel discovery and 
development of drugs interfering with RAS signaling.
Zimmermann G, Papke B, Ismail S, et al. Small molecule 
inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS 
signalling. Nature 2013 (E-pub ahead of print).
•	 Genome-Wide Association 
Study of Genetic 
Predictors of Overall 
Survival for Non-Small 
Cell Lung Cancer in Never 
Smokers
70 paired tumor and normal tissues were also evaluated. Ninety-four 
loci were shown to be significant for OS in the MD Anderson and 
Mayo populations, of which 2 variants (rs6901416 and rs10766739) 
out of the top 25 were also significant in the Taiwanese population 
and were associated with reduced median survival time of at least 8 
and 5 months, respectively in these 3 populations. Six other variants 
were correlated with expression levels of 6 genes (LEMD3, TMBIM, 
ATXN7L2, SHE, ITIH2, and NUDT5), which were differentially 
expressed in tumor compared with normal lung. The findings 
identified potential prognostic markers for never smoker patients with 
NSCLC and the eQTL analysis implicated several novel genes for the 
underlying mechanism of lung cancer survival in never smokers.
Wu X, Wang L, Ye Y, et al. Genome-wide association study of 
genetic predictors of overall survival for non-small cell lung cancer 
in never smokers. Cancer Res 2013 (E-pub ahead of print).
predictors regardless of treatment. The authors concluded that tumor 
stage and CT-derived tumor heterogeneity are strong independent 
predictors of survival of NSCLC patients. Measurement of tumor 
heterogeneity on CT could allow stratification of NSCLC patients for 
therapy and monitoring for tumor recurrence.
Win T, Miles KA, Janes SM, et al. Tumor heterogeneity and 
permeability as measured on the CT component of PET/CT predict 
survival in patients with non-small cell lung cancer. Clin Cancer 
Res 2013 (E-pub ahead of print).
populations were followed-up for an average of 22.6 ± 13.3 months 
and 28.5 ± 13.2 months for the feasibility and validation studies, 
respectively. The biomarkers in image analysis were PET/CT textural 
heterogeneity, DCE-CT permeability, and FDG uptake (SUVmax). 
The results showed that tumor stage, vascularity and heterogeneity 
(measured on both the CT and PET components of PET/CT) were 
all significant survival predictors but not tumor SUV
max
 in univariate 
analysis. Multivariate analysis revealed that CT-derived tumor 
heterogeneity, permeability and tumor stage were independent survival 
KRAS mutations are the predominant oncogenic abnormalities in 
cancers such as lung, pancreatic and colorectal cancers. But clinical 
intervention using pharmacological inhibitors of RAS has not been 
successful. RAS proteins are synthesized in the cytoplasm and 
inactive until being post-translationally modified for membrane 
association and hence oncogenic signaling activity. Previous study 
showed that the prenyl-binding protein, PDEδ is involved in the 
trafficking of RAS proteins to the plasma membrane and affects 
The authors conducted the first genome-wide association study 
(GWAS) among never smokers with non-small cell lung cancer 
(NSCLC) to determine the genetic predictors of overall survival 
(OS) in this population. Two independent populations with never 
smoker NSCLC patients from the MD Anderson Cancer Center and 
the Mayo Clinic were included for consistency meta-analysis. The 
top 25 variants were validated in a large Taiwanese population of 
never smoker lung cancer patients. Expression quantitative trait loci 
(eQTL) and differential expression of genes around the top loci in 
•	 Crizotinib Versus 
Chemotherapy in 
Advanced ALK-Positive 
Lung Cancer
either crizotinib orally (250 mg twice daily) or chemotherapy 
intravenously (pemetrexed at 500 mg/m2 or docetaxel at 75 mg/
m2) every 3 weeks. The findings demonstrated that crizotinib is 
more superior to chemotherapy with markedly improved median 
progression-free survival (7.7 months vs. 3 months) and response 
rates (65% vs. 20%) although there was no significant difference 
in overall survival between the two groups. Patients treated with 
crizotinib also experienced fewer symptoms of lung cancer and 
better quality of life compared with chemotherapy.
Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus 
chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 
2013;368:2385–2394.
Significant efficacy from treatments with crizotinib has been linked 
to ALK rearrangements. Shaw and colleagues conducted a phase 
III, open-label trial to investigate whether crizotinib is superior 
to chemotherapy in treating patients with advanced lung cancer 
bearing ALK rearrangements. Patients with locally advanced 
or metastatic ALK-positive lung cancer and previously treated 
with platinum-based therapy, were randomly assigned to receive 
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NEWS IN BRIEF
•	 Erlotinib Approved 
Concurrently With 
EGFR Mutation Test for 
Advanced NSCLC
factor receptor (EGFR) mutations: exon 19 deletions or 
exon 21 (L858R) substitution. This approval is granted 
as a result of a randomised, multicenter, open label 
trial comparing erlotinib to platinum-based doublet 
chemotherapy in patients with advanced NSCLC bearing 
the aforementioned EGFR mutations. The trial results 
demonstrated improved median progression-free survival, 
median overall survival and objective response rate with 
erlotinib compared with platinum-based chemotherapy. 
Most frequent side effects include rash, diarrhea, 
asthenia, cough, dyspnea and decreased appetite.
•	 EMCTO 2013: Stereotactic 
Ablative Radiotherapy 
for Patients with Multiple 
Primary Lung Cancers
combination with surgery for the second lesion. Survival, 
relapse and toxicity were assessed in addition to analysis 
on ipsilateral and bilateral lung lesions. The results showed 
a median overall survival of 31 months, a 5% incidence 
of grade 3 or higher toxicity and an overall lesion control 
rate of 78%, supporting SABR (alone or combined with 
surgery) as an effective and safe alternative for multiple 
primary lung cancers in surgically unfit candidates. On 
the other hand, the analysis on ipsilateral and bilateral 
lesions revealed poor local control rates post SABR for 
ipsilateral lesions (58%) compared with bilateral lesions 
(92%). The higher incidence of regional relapses overall 
for synchronous lesions vs. single lesions (17% vs. 12%) 
may suggest the need for invasive nodal staging.
•	 EMCTO 2013: Biomarker 
Evaluation of the 
Coexistence of EGFR 
Mutations and HER2 Gene 
Amplifications in a Large 
NSCLC Population
HER2 gene amplification in this population. The study 
showed no association of HER2 amplification with 
EGFR T790M mutation. There were 3 cases identified 
with coexistence of HER2 gene amplification and EGFR 
mutations (L858R, A859T and E746_A750del), and 7 
cases showing coexistence of HER2 gene amplification 
with KRAS mutations (39% KRAS activating mutation). 
Double EGFR mutations (L858R/T790M and 
E746_A750del/T790M) were discovered in only 2 
cases. HER2 amplification was recognized to play a 
role in acquired resistance to EGFR-TKIs in a distinct 
subset of NSCLC without the EGFR T790M mutation. 
The findings provide possible strategy to overcome 
resistance by targeting both HER2 and EGFR activities.
The FDA approved erlotinib (Tarceva, Astellas Pharma Inc.) for 
first-line treatment of patients with metastatic non-small cell lung 
cancer (NSCLC), in conjunction with the cobas® EGFR Mutation 
Test to select these patients with tumor harboring epidermal growth 
At the European Multidisciplinary Conference in Thoracic Oncology 
(EMCTO), Dr. Griffioen from the VU University Medical Center, 
Amsterdam, Netherlands presented findings that demonstrated 
stereotactic ablative radiotherapy (SABR) could be used to treat 
patients with multiple primary lung cancers who were unfit for 
surgery. The study population comprised 62 patients with multiple 
primary lung cancers in their institute from 2003 to 2012, who 
received SABR, either as a single modality for both lesions or in 
Dr Zoran Gatalica from Creighton University School of Medicine, 
Omaha led a team to evaluate the frequency of coexistence of 
EGFR mutations and HER2 gene amplifications. They characterized 
the molecular profiles of 2271 patients with non-small cell lung 
cancer (NSCLC) by immunohistochemistry, FISH and sequencing. 
According to their presentation at the European Multidisciplinary 
Conference in Thoracic Oncology (EMCTO), the analysis revealed 
12% of EGFR mutation, 32% of KRAS mutation and only 4% of 
•	 EMCTO 2013: The 
Performance of LDCT 
Screening in the First Three 
Rounds of the NELSON 
Trial
The Dutch-Belgian Randomized Lung Cancer Screening 
Trial (NELSON) is the largest randomized trial in 
Europe to determine if low-dose computed tomography 
(LDCT) screening in high-risk individuals for lung 
cancer will reduce the 10-year lung cancer mortality 
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•	 ASCO 2013: PFS Improved 
with Sunitinib in Small-Cell 
Lung Cancer
over placebo (3.77 months vs. 2.30 months) whereas 
improvement in overall survival (OS) with sunitinib was 
not significant although showed potential for benefits 
(8.95 months vs. 6.89 months). Overall rate of grade 
3/4 toxicities with sunitinib was 46.5% vs. 19.5% for 
placebo. Fatigue and thrombocytopenia were among the 
most common toxicities. Dr. Ready, who presented the 
findings at the American Society of Clinical Oncology 
(ASCO) Annual Meeting 2013, concluded that a phase III 
study of this treatment should be conducted based on the 
improvement observed.
by at least 25%. It is also the first study to employ software in 
calculating nodule volume doubling time to define positive and 
negative results. Data presented at the European Multidisciplinary 
Conference in Thoracic Oncology (EMCTO) was derived from 
the first three rounds of the trial and 5.5 years of follow-up with 
risk calculations. The criteria for NELSON trial include lung 
nodules with a volume >500mm3 or a volume-doubling time 
<400 days are defined as positive; nodule volumes 50-500mm3 or 
volume-doubling times 400–600 days are indeterminate; the rest 
are negative. The results demonstrated a positive predictive value 
of 40.6% for the LDCT strategy. The outcome of the first screen 
was shown to affect the risk of lung cancer detected by screening 
over the 5.5 year: 1.0% risk following a negative primary scan at 
baseline, 5.7% following an indeterminate baseline and 48.3% 
following a positive baseline scan. This finding supports LDCT for 
lung cancer screening. Although the screening is not recommended 
in the present guideline of the European Society for Medical 
Oncology (ESMO) for diagnosis, treatment and follow-up of early-
stage and non-metastatic NSCLC, new development and data are 
under review for guideline update.
The ALLIANCE trial is a randomized phase II study to assess a 
lower dose of sunitinib (150 mg on day 1 and then 37.5 mg daily until 
disease progression) in a maintenance therapy setting for patients 
with small-cell lung cancer following standard chemotherapy regimen 
of cisplatin or carboplatin and etoposide. The results demonstrated a 
significantly improved progression-free survival (PFS) with sunitinib 
•	 ASCO 2013: CUSTOM Trial 
Indicates Genetic Testing 
Timely for Personalized 
Treatment
accounted for 19.7% and 25.2%, respectively. Erlotinib 
exhibited high efficacy in patients with EGFR mutations, 
which agrees with earlier findings. On the other hand, 
selumetinib treatment did not show benefit in patients 
with KRAS mutations. The CUSTOM trial illustrates 
that it is feasible to use genetic analysis of common 
mutations to predict response to therapy and guide 
treatment in a timely manner (completed in 2 weeks), 
while it is challenging to do so for rare mutations in 
patients with small cell lung or thymic cancers.
CUSTOM is the first completed prospective trial that employed 
genetic analysis of approximately 200 genes to assign cancer 
treatment for patients with advanced non–small cell lung cancer 
(NSCLC), small cell lung cancer, or thymic cancer. EGFR 
and KRAS mutations were the most frequent genetic changes, 
•	 ASCO 2013: Standard-Dose 
(60 Gy) Vs. High-Dose  
(74 Gy) Radiation for Stage 
III Non-Small Cell Lung 
Cancer
a 37% increased risk of local failure (65 failures vs. 
81 failures, respectively). High-dose therapy resulted 
in higher local recurrence rates (34.3% vs. 25.1%, 
respectively), and higher distant recurrence rates (44% 
vs. 35.3%, respectively). Median survival and the 
estimated 18-month overall survival rates in the high-
dose therapy were lower compared with the standard-
dose therapy: 19.5 months vs. 28.7 months, and 53.9% 
vs. 66.9%, respectively. Esophagitis happened at higher 
rates in patients receiving high-dose therapy (21% vs. 
7%, respectively). The findings of this randomized 
phase III demonstrated that standard-dose of 60 Gy 
conformal radiotherapy is more effective and safer than 
high-dose of 74 Gy radiotherapy in patients with stage 
III NSCLC treated with chemotherapy. It was therefore 
recommended that radiation oncologists should reduce 
the use of high-dose radiotherapy for these patients.
The investigators reported at ASCO 2013 the first objective of the 
RTOG 0617 trial, which was to compare the overall survival (OS) 
of patients with stage III non-small cell lung cancer (NSCLC) 
receiving the standard-dose (60 Gy) and high-dose (74 Gy) 
conformal chemoradiotherapy. The study randomly assigned 
464 patients to standard-dose and high-dose radiotherapy with 
concurrent chemotherapy (paclitaxel and carboplatin). Patients 
in each treatment arm were also randomized to be treated with 
or without cetuximab (Erbitux), the results of which will be 
available in 2014. Compared with patients in the standard-dose 
arm, those in the high-dose arm had a 56% increased risk of 
death (overall survival of 90 deaths vs. 117, respectively) and 
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•	 ASCO 2013: High Response 
Rate From Novel Second 
Generation ALK Inhibitor in 
Advanced NSCLC
there was a 93.5% objective response and 2.2% stable 
response. Rapid response to treatment was achieved, in 
which partial response was observed within 3 weeks in 
65% of patients and within 6 weeks in 87% patients. 
More than 30% of tumor shrinkage was found in all 
patients. There were 11% of patients reported with 
serious adverse events but no grade 4 adverse events 
or deaths. The study is still ongoing while additional 
studies to evaluate its efficacy in patients with crizotinib 
resistance are underway. The findings so far suggested 
that CH5424802 could be an effective and safe 
alternative treatment for patients with NSCLC bearing 
ALK rearrangements.
•	 ASCO 2013: Promising 
Early Trial Results for 
PD-1 and PD-L1 Targeting 
Immunotherapies
response rate was 21%, including 36% of PD-L1 positive 
tumors and 13% of PD-L1-negative tumors. In NSCLC 
(n=41), 22% tumors responded, of which 80% were 
PD-L1 positive and 14% PD-L1 negative. PD-L1 was 
detected in all squamous and 67% nonsquamous NSCLC 
in this population.The responses were rapid with some 
patients experiencing tumor regression within days 
of starting treatment. Prolonged disease stabilization 
was observed and no deaths from MPDL3280A were 
reported. Cancer-related symptoms were reported to have 
improved with the treatment. Further clinical studies are 
underway to confirm the findings and validate the use of 
the PD-L1 status in patient stratification. On the other 
hand, concurrent therapy with the anti-PD-1 antibody, 
nivolumab (BMS-936558), and ipilimumab, which targets 
cytotoxic T-lymphocyte antigen 4 (CTLA-4) produced 
promising early data in advanced melanoma. This 
combination is currently being evaluated in NSCLC and 
renal cell cancer as well.
CH5424802, a potent and selective oral ALK inhibitor, elicits 
response in tumor cell lines with ALK alterations, which 
includes those linked to crizotinib resistance. Patients with 
ALK-rearrangements in stage IIIB, IV or recurrent NSCLC 
with prior chemotherapy were enrolled in a Japanese phase I-II 
study (AF-100JP) aimed to investigate the efficacy and safety of 
CH5424802. In ALK inhibitor–naive NSCLC patients bearing 
ALK rearrangements receiving CH5424802 300 mg twice daily, 
Tumor cells evade host’s immune system via programmed death 
1 protein (PD-1) and its ligand (PD-L1). Antibodies blocking 
expression or activity of PD-1 and PD-L1 would potentially 
restore host’s immune responses. Anti-PD-L1, MPDL3280A, 
was engineered to have improved safety and efficacy compared 
to earlier PD-L1 or PD-1 targeted agents. A multicenter phase 
I study was conducted in 140 patients with locally advanced or 
metastatic solid tumors (including cancers of the lung, kidney, 
melanoma, colon, stomach, and head and neck), who had disease 
progression despite prior therapies. MPDL3280A was administered 
intravenously every 3 weeks until disease progression.Robust 
single-agent activity was observed with MPDL3280A across a 
range of solid tumors, with the greatest response in non-small cell 
lung cancer (NSCLC), renal cancer and melanoma. The overall 
